A new study reveals the remote patient monitoring industry (RPM) is expected to grow by 12.5% in the next ten years. And another study shows that almost half of healthcare providers believe that remote patient monitoring will be as prevalent as in-person monitoring within the next five years. All this comes at a time when Apple also recently announced new heart and health monitoring features for their latest smartwatch. Waqaas Al-Siddiq, CEO and founder of Biotricity, discusses how RPM will continue to improve patient outcomes and why RPM tech is poised for rapid growth. Waqaas shares his insights on whether wearable devices such as the Apple Watch can replace other devices for patients with heart conditions. We also explore what the future holds for remote patient monitoring technology. About Biotricity Biotricity is a medical technology company committed to improving healthcare by developing solutions that aid chronic disease prevention and management. Biotricity’s premier product is Bioflux, an ECG monitoring system that will be prescribed by physicians to diagnose and remotely monitor cardiac patients.  Biotricity is expanding medical-grade monitoring into the consumer market via its Biolife solution, which empowers users to self-manage chronic conditions. Biolife helps users make lifestyle changes by combining medically relevant ECG data with social media interactivity and a lifestyle log.  Biotricity’s R&D continues to focus on the preventative healthcare market, with a vision of putting health management into the hands of the individual. The company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system.